+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mental Health Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design (Interventional, Observational), By Sponsor, By Disorder (Anxiety Disorders, Depression, Schizophrenia), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830982
The global mental health clinical trials market size is expected to reach USD 5.10 billion by 2030, registering a CAGR of 8.3% over the forecast period. Mental health has become a major area of concern globally, and the need for effective treatments and therapies has become more pressing than ever. Due to the rising incidence of mental diseases like bipolar disorder, anxiety, and depression, mental health has become a major global problem. The market for mental health clinical trials has expanded as a result of the rising prevalence of these disorders and the increased demand for effective treatments and cures.

Also, the industry has expanded as a result of governments and private groups investing more money in clinical trials and mental health research. The need for effective therapies has grown as a result of the increased knowledge and openness surrounding mental health. Additionally, new avenues for mental health therapies have been made possible by technical developments like telemedicine and digital pharmaceuticals. The market for mental health clinical trials is expanding as a result of these developments, which have made it possible for patients to receive more creative and individualized therapies.

Due to their strong dedication to research and development, which is fostering the creation of novel therapies for mental health diseases, the pharmaceutical and biopharmaceutical market has dominated the market for mental health clinical trials. Clinical trials are being substantially funded by pharmaceutical and biopharmaceutical companies in order to evaluate the efficacy and safety of their products before regulatory agencies like the FDA approve them. In recent years, several pharmaceutical and biopharmaceutical companies have made significant advancements in developing mental health treatments.

For instance, in 2019, U. S. FDA approved Spravato, a nasal spray to be used for the treatment of depression in adults. The drug contains a chemical called Esketamine, which works differently from traditional antidepressants and can produce rapid results in patients. The market for mental health clinical trials is anticipated to expand as long as pharmaceutical and biopharmaceutical businesses continue to make research and development investments. Their emphasis on the creation of efficient cures and treatments for mental health issues has the potential to greatly enhance the lives of people with these conditions.

Mental Health Clinical Trials Market Report Highlights

  • The phase 3 segment dominated the market in 2022 with a maximum revenue share of 31.0%. Phase 3 clinical trials are the most advanced stage of drug development, involving large numbers of patients, and thus, they dominate the market.
  • Observational category in the study design segment is anticipated to witness fastest growth of 8.6%. Observational studies are less invasive, have fewer ethical considerations, and are more cost-effective, which makes them the preferred study design
  • Pharmaceutical and biopharmaceutical companies dominated the mental health clinical trials market in the sponsor segment with revenue share of 39.6%. This is due to their strong commitment to research and development, which drives the development of new and innovative treatments for mental health disorders
  • Depression dominated the mental health clinical trials market in the disorder segment with a revenue share of 22.6% in 2022, due to its high prevalence, significant economic burden, and increasing demand for effective treatments
  • North America held the maximum revenue share of 50.3% in the global market in 2022 due to factors such as the presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities. This region has a well-established healthcare system that supports the development and commercialization of new therapies, which contributes to its dominance in the market

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Scope
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Mental Health Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing prevalence of mental health issues across the globe
3.2.1.2. Increasing drug pipeline for mental health conditions
3.2.2. Market restraint analysis
3.2.2.1. Limited awareness in developing economies pertaining to mental health issues
3.3. Dental Regeneration: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.4. COVID-19 Impact Analysis
Chapter 4. Mental Health Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Mental Health Clinical Trials Market Share, 2022 & 2030
4.3. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
4.3.1. Phase I
4.3.1.1. Phase I Market 2018 to 2030 (USD Million)
4.3.2. Phase II
4.3.2.1. Phase II Market 2018 to 2030 (USD Million)
4.3.3. Phase III
4.3.3.1. Phase III Market 2018 to 2030 (USD Million)
4.3.4. Phase IV
4.3.4.1. Phase IV Market 2018 to 2030 (USD Million)
Chapter 5. Mental Health Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Mental Health Clinical Trials Market Share, 2022 & 2030
5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.3.1. Interventional
5.3.1.1. Interventional Market 2018 to 2030 (USD Million)
5.3.2. Observational
5.3.2.1. Observational Market 2018 to 2030 (USD Million)
5.3.3. Others
5.3.3.1. Others Market 2018 to 2030 (USD Million)
Chapter 6. Mental Health Clinical Trials Market: Sponsor Estimates & Trend Analysis
6.1. Definitions and Scope
6.2. Mental Health Clinical Trials Market Share, 2022 & 2030
6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.3.1. Interventional Pharmaceutical & Biopharmaceutical Companies
6.3.1.1. Hospitals & Universities Market 2018 to 2030 (USD Million)
6.3.2. Government Agencies
6.3.2.1. Government Agencies Market 2018 to 2030 (USD Million)
6.3.3. Others
6.3.3.1. Others Market 2018 to 2030 (USD Million)
Chapter 7. Mental Health Clinical Trials Market: Disorder Estimates & Trend Analysis
7.1. Definitions and Scope
7.2. Mental Health Clinical Trials Market Share, 2022 & 2030
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.3.1. Anxiety Disorders
7.3.1.1. Anxiety Disorders Market 2018 to 2030 (USD Million)
7.3.2. Depression
7.3.2.1. Depression Market 2018 to 2030 (USD Million)
7.3.3. Bipolar affective disorder
7.3.3.1. Bipolar affective disorder Market 2018 to 2030 (USD Million)
7.3.4. Dissociation and dissociative disorders
7.3.4.1. Dissociation and dissociative disorders Market 2018 to 2030 (USD Million)
7.3.5. Schizophrenia
7.3.5.1. Schizophrenia Market 2018 to 2030 (USD Million)
7.3.6. Others
7.3.6.1. Others Market 2018 to 2030 (USD Million)
Chapter 8. Mental Health Clinical Trials Market: Regional Estimates & Trend Analysis
8.1. Regional market share analysis, 2022 & 2030
8.2. Market Size, & Forecasts, Revenue and Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. North America Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.3.2. U.S.
8.3.2.1. U.S. Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.3.3. Canada
8.3.3.1. Canada Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. UK Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Germany Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.4.3. France
8.4.3.1. France Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Italy Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Spain Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.4.6. Denmark
8.4.6.1. Denmark Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Sweden Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.4.8. Norway
8.4.8.1. Norway Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Japan Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.5.2. China
8.5.2.1. China Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.5.3. India
8.5.3.1. India Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Australia Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.5.5. Thailand
8.5.5.1. Thailand Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.5.6. South Korea
8.5.6.1. South Korea Mental Health Clinical Trials Market, 2018 - 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Brazil Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.6.2. Mexico
8.6.2.1. Mexico Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.6.3. Argentina
8.6.3.1. Argentina Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. South Africa Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Saudi Arabia Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.7.3. UAE
8.7.3.1. UAE Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Kuwait Mental Health Clinical Trials Market , 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Profiles
9.1.1. ICON Plc.
9.1.1.1. Company overview
9.1.1.2. Financial Performance
9.1.1.3. Service benchmarking
9.1.1.4. Strategic initiatives
9.1.2. Eli Lilly Company
9.1.2.1. Company overview
9.1.2.2. Financial performance
9.1.2.3. Service benchmarking
9.1.2.4. Strategic initiatives
9.1.3. Caidya
9.1.3.1. Company overview
9.1.3.2. Financial performance
9.1.3.3. Service benchmarking
9.1.3.4. Strategic initiatives
9.1.4. Syneous Health
9.1.4.1. Company overview
9.1.4.2. Financial performance
9.1.4.3. Service benchmarking
9.1.4.4. Strategic initiatives
9.1.5. Novo Nordisk
9.1.5.1. Company overview
9.1.5.2. Financial performance
9.1.5.3. Service benchmarking
9.1.5.4. Strategic initiatives
9.1.6. Pharmaceutical Product Development, LLC
9.1.6.1. Company overview
9.1.6.2. Financial performance
9.1.6.3. Service benchmarking
9.1.6.4. Strategic initiatives
9.1.7. Parexel International Corporation
9.1.7.1. Company overview
9.1.7.2. Financial performance
9.1.7.3. Service benchmarking
9.1.7.4. Strategic initiatives
9.1.8. Corcept
9.1.8.1. Company overview
9.1.8.2. Financial performance
9.1.8.3. Service benchmarking
9.1.8.4. Strategic initiatives
9.1.9. Labcorp Drug Development
9.1.9.1. Company overview
9.1.9.2. Financial performance
9.1.9.3. Service benchmarking
9.1.9.4. Strategic initiatives
9.1.10. IQVIA
9.1.10.1. Company overview
9.1.10.2. Financial performance
9.1.10.3. Service benchmarking
9.1.10.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modelling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary research pattern
Fig. 8 Primary interviews in North America
Fig. 9 Primary interviews in Europe
Fig. 10 Primary interviews in Asia Pacific
Fig. 11 Primary interviews in Latin America
Fig. 12 Primary interviews in MEA
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Segment Snapshot
Fig. 16 Competitive Landscape Snapshot
Fig. 17 Mental Health Clinical Trials Market segmentation
Fig. 18 Parent market outlook (2022)
Fig. 19 Related/ancillary market outlook (2022)
Fig. 20 Market driver relevance analysis (Current & future impact)
Fig. 21 Current shared services and outsourcing usage levels
Fig. 22 Market restraint relevance analysis (Current & future impact)
Fig. 23 Porter’s five forces analysis
Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 25 Mental Health Clinical Trials Market Phase outlook: Segment dashboard
Fig. 26 Mental Health Clinical Trials: phase movement analysis
Fig. 27 Phase I market, 2018 - 2030 (USD Million)
Fig. 28 Phase II market, 2018 - 2030 (USD Million)
Fig. 29 Phase III market, 2018 - 2030 (USD Million)
Fig. 30 Phase IV market, 2018 - 2030 (USD Million)
Fig. 31 Mental Health Clinical Trials Market study design outlook: Segment dashboard
Fig. 32 Interventional market, 2018 - 2030 (USD Million)
Fig. 33 Observational market, 2018 - 2030 (USD Million)
Fig. 34 Others market, 2018 - 2030 (USD Million)
Fig. 35 Mental Health Clinical Trials Market sponsor outlook: Segment dashboard
Fig. 36 Mental Health Clinical Trials Market: sponsor movement analysis
Fig. 37 Pharmaceutical & Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
Fig. 38 Government Agencies market, 2018 - 2030 (USD Million)
Fig. 39 Others market, 2018 - 2030 (USD Million)
Fig. 40 Mental Health Clinical Trials Market Disorder outlook: Segment dashboard
Fig. 41 Mental Health Clinical Trials Market: Disorder movement analysis
Fig. 42 Anxiety Disorders market, 2018 - 2030 (USD Million)
Fig. 43 Depression market, 2018 - 2030 (USD Million)
Fig. 44 Bipolar affective disorder market, 2018 - 2030 (USD Million)
Fig. 45 Dissociation and dissociative disorders market, 2018 - 2030 (USD Million)
Fig. 46 Schizophrenia market, 2018 - 2030 (USD Million)
Fig. 47 Others disorder market, 2018 - 2030 (USD Million)
Fig. 48 Regional marketplace: Segment dashboard
Fig. 49 Regional outlook, 2022 & 2030
Fig. 50 North America market, 2018 - 2030 (USD Million)
Fig. 51 U.S. market, 2018 - 2030 (USD Million)
Fig. 52 Canada market, 2018 - 2030 (USD Million)
Fig. 53 Europe market, 2018 - 2030 (USD Million)
Fig. 54 Germany market, 2018 - 2030 (USD Million)
Fig. 55 UK market, 2018 - 2030 (USD Million)
Fig. 56 France market, 2018 - 2030 (USD Million)
Fig. 57 Italy market, 2018 - 2030 (USD Million)
Fig. 58 Spain market, 2018 - 2030 (USD Million)
Fig. 59 Denmark market, 2018 - 2030(USD Million)
Fig. 60 Sweden market, 2018 - 2030 (USD Million)
Fig. 61 Norway market, 2018 - 2030 (USD Million)
Fig. 62 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 63 China market, 2018 - 2030 (USD Million)
Fig. 64 Japan market, 2018 - 2030 (USD Million)
Fig. 65 India market, 2018 - 2030 (USD Million)
Fig. 66 Australia market, 2018 - 2030 (USD Million)
Fig. 67 South Korea market, 2018 - 2030 (USD Million)
Fig. 68 Latin America market, 2018 - 2030 (USD Million)
Fig. 69 Brazil market, 2018 - 2030 (USD Million)
Fig. 70 Mexico market, 2018 - 2030 (USD Million)
Fig. 71 Argentina market, 2018 - 2030 (USD Million)
Fig. 72 MEA market, 2018 - 2030 (USD Million)
Fig. 73 South Africa market, 2018 - 2030 (USD Million)
Fig. 74 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 75 UAE market, 2018 - 2030 (USD Million)
Fig. 76 Kuwait market, 2018 - 2030 (USD Million)

Companies Mentioned

  • ICON Plc.
  • Eli Lilly Company
  • Caidya
  • Syneous Health
  • Novo Nordisk
  • Pharmaceutical Product Development, LLC
  • Parexel International Corporation
  • Corcept
  • Labcorp Drug Development
  • IQVIA

Methodology

Loading
LOADING...

Table Information